Skip to main content

Advertisement

SpringerLink
Log in

Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis

  • Rhinology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the efficacy of chemotherapy among intermediate-risk (stage II/T3N0) nasopharyngeal carcinoma (NPC) patients receiving radiotherapy (RT).

Methods

We identified stage II/T3N0 NPC patients who received radiotherapy with or without chemotherapy from the Surveillance, Epidemiology and End Results database (2004–2019). Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan–Meier method with log-rank test and Cox proportional hazards models to evaluate the efficacy of chemotherapy. Subgroup analysis was also conducted based on the baseline characteristics. Propensity score matching (PSM) was performed to balance the intergroup covariates.

Results

A total of 1623 patients were enrolled in the study, 1444 received chemoradiotherapy (CRT) and 179 received RT alone. CRT, compared to RT alone, was independently associated with a better OS (HR 0.57, 95% CI 0.45–0.71) and CSS (HR 0.55, 95% CI 0.39–0.79). After PSM, similar results were obtained, and CRT was superior to RT alone in terms of OS (HR 0.60, 95% CI 0.39–0.92) and CSS (HR 0.60, 95% CI 0.40–0.91). Subgroup analysis revealed that OS benefits from CRT were mainly observed in T0-2N1(HR 0.51, 95% CI 0.38–0.70) and T3N0 (HR 0.64, 95% CI 0.42–0.98) rather than T2N0 (HR 1.00, 95% CI 0.51–1.94). Interestingly, after PSM, OS benefits were still seen in T0-2N1 (HR 0.44, 95% CI 0.24–0.82), while not seen in T2N0 (HR 1.83, 95% CI 0.56–5.97) and T3N0 (HR 0.56, 95% CI 0.28–1.12).

Conclusion

For T0-2N1 NPC patients, CRT was superior to RT alone with better survival, whereas, for T2-3N0 patients, CRT was comparable to RT alone. Prospective large studies should be encouraged to verify the results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

    Article  PubMed  Google Scholar 

  2. Wee JT, Ha TC, Loong SL et al (2010) Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer 29:517–526

    Article  CAS  PubMed  Google Scholar 

  3. Yang XL, Wang Y, Liang SB et al (2018) Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. BMC Cancer 18:606

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lin YH, Huang TL, Chien CY et al (2018) Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. Radiat Oncol 13:45

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhang Y, Chen L, Hu GQ et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381:1124–1135

    Article  CAS  PubMed  Google Scholar 

  6. Bongiovanni A, Vagheggini A, Fausti V et al (2021) Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: an updated network meta-analysis. Crit Rev Oncol Hematol 160:103244

    Article  PubMed  Google Scholar 

  7. Verma V, Ryckman JM, Simone CB 2nd et al (2018) Patterns of care and outcomes with the addition of chemotherapy to radiation therapy for stage I nasopharyngeal cancer. Acta Oncol 57:257–261

    Article  CAS  PubMed  Google Scholar 

  8. Huang X, Chen X, Zhao C et al (2020) Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol 10:1314

    Article  PubMed  PubMed Central  Google Scholar 

  9. Li XY, Chen QY, Sun XS et al (2019) Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer 110:24–31

    Article  PubMed  Google Scholar 

  10. Ahmed Z, Kujtan L, Kennedy K et al (2019) The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database. Cancer Med 8:1500–1507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wu P, Zhao Y, Xiang L et al (2020) Management of chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a review. Cancer Manag Res 12:957–963

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chen FP, Lin L, Liang JH et al (2021) Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Ther Adv Med Oncol 13:17588359211052416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Guo R, Tang LL, Mao YP et al (2019) Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 125:79–89

    Article  CAS  PubMed  Google Scholar 

  14. Wang L, Wu Z, Cheng W et al (2021) Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up. Radiat Oncol 16:215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317

    Article  CAS  PubMed  Google Scholar 

  16. Chen Y, Sun Y, Liang SB et al (2013) Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 119:2230–2238

    Article  CAS  PubMed  Google Scholar 

  17. Lee AW, Tung SY, Chan AT et al (2011) A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 98:15–22

    Article  PubMed  Google Scholar 

  18. Lee AWM, Tung SY, Ng WT et al (2017) A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer 123:4147–4157

    Article  CAS  PubMed  Google Scholar 

  19. Sun XS, Chen WH, Liu SL et al (2019) Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: a propensity score matching analysis using a large cohort. Cancer Med 8:4214–4225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sun XS, Li XY, Xiao BB et al (2020) Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: a study based on a phase III randomized clinical trial with 10-year follow-up. Oral Oncol 100:104490

    Article  PubMed  Google Scholar 

  21. Aftab O, Liao S, Zhang R et al (2020) Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol 15:66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhang F, Zhang Y, Li WF et al (2015) Efficacy of concurrent chemotherapy for intermediate risk NPC in the intensity-modulated radiotherapy era: a propensity-matched analysis. Sci Rep 5:17378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zhang LN, Gao YH, Lan XW et al (2015) Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Oncotarget 6:44019–44029

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wang X, Wang Z, Chen Y et al (2022) Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma. Am J Otolaryngol 43:103235

    Article  PubMed  Google Scholar 

  25. Sze HC, Ng WT, Chan OS et al (2012) Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 48:162–167

    Article  PubMed  Google Scholar 

  26. Mi JL, Meng YL, Wu HL et al (2020) Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years). Strahlenther Onkol 196:270–279

    Article  PubMed  Google Scholar 

  27. Verma V, Surkar SM, Moreno AC et al (2018) Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer. Cancer Med 7:1604–1611

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zeng Q, Xiang YQ, Wu PH et al (2015) A matched cohort study of standard chemo-radiotherapy versus radiotherapy alone in elderly nasopharyngeal carcinoma patients. PLoS ONE 10:e0119593

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ng AWY, Tung SY, Cheung AKW et al (2015) No role of using chemoradiation in T2N0 and T1N1 with small lymph node size stage II nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 93:E306–E307

    Article  Google Scholar 

  30. Chen S, Yang D, Liao X et al (2021) Failure patterns of recurrence and metastasis after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma: results of a multicentric clinical study. Front Oncol 11:693199

    Article  PubMed  Google Scholar 

  31. Cao C, Xu Y, Huang S et al (2021) Locoregional extension patterns of nasopharyngeal carcinoma detected by FDG PET/MR. Front Oncol 11:763114

    Article  PubMed  PubMed Central  Google Scholar 

  32. Zhao Y, Liao X, Wang Y et al (2022) Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy. Radiother Oncol 172:10–17

    Article  PubMed  Google Scholar 

  33. Mao Y, Wang S, Lydiatt W et al (2021) Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: potential improvement for future editions of N category systems. Radiother Oncol 157:114–121

    Article  PubMed  Google Scholar 

  34. Tsai TY, Chou YC, Lu YA et al (2021) The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis. Oral Oncol 122:105518

    Article  PubMed  Google Scholar 

  35. Hu Y, Lu T, Huang SH et al (2019) High-grade radiologic extra-nodal extension predicts distant metastasis in stage II nasopharyngeal carcinoma. Head Neck 41:3317–3327

    Article  PubMed  Google Scholar 

  36. Lu T, Hu Y, Xiao Y et al (2019) Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. Oral Oncol 99:104438

    Article  PubMed  Google Scholar 

  37. Chin O, Yu E, O’Sullivan B et al (2021) Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiother Oncol 165:94–102

    Article  PubMed  Google Scholar 

  38. Zhang W, Chen Y, Chen L et al (2015) The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 94:e845

    Article  CAS  PubMed  Google Scholar 

  39. Kim KY, Le QT, Yom SS et al (2017) Clinical Utility of Epstein-Barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 98:996–1001

    Article  PubMed  Google Scholar 

  40. Chan AT, Lo YM, Zee B et al (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614–1619

    Article  CAS  PubMed  Google Scholar 

  41. Tang SQ, Chen L, Li WF et al (2021) Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother Oncol 167:179–186

    Article  PubMed  Google Scholar 

  42. Liang H, Lv X, Wang L et al (2018) The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Ther Adv Med Oncol 10:1758835918782331

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lee AWM, Lee VHF, Ng WT et al (2021) A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer 153:109–122

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The author(s) received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, 71 He-di Road, Nanning, 530021, People’s Republic of China

    Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang & Xiao-Dong Zhu

  2. Department of Oncology, Affiliated Wu-Ming Hospital of Guangxi Medical University, Nanning, People’s Republic of China

    Xiao-Dong Zhu

Authors
  1. Yao-Can Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai-Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhong-Guo Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Dong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Dong Zhu.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest in this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, YC., Chen, KH., Liang, ZG. et al. Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis. Eur Arch Otorhinolaryngol 280, 1793–1802 (2023). https://doi.org/10.1007/s00405-022-07726-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-022-07726-8

Keywords

Search

Navigation